Cytokinetics (CYTK): Frazier Life Sciences Management, L.P. added to its stake +336K shares
Frazier Life Sciences Management, L.P. added to its stake in Cytokinetics, per its Q3 2025 13F.
- 890K
- Shares reported · +336K vs prior quarter
- 1.5%
- Disclosed portfolio weight
- $48.9M
- Reported value
- Holdings as of
- Sep 30, 2025
- Filed
- Nov 14, 2025
What stands out in this filing
- 554,731 shares in Q2 2025, 890,445 now (+60.5% in share count).
- Reported at $48.9M, 1.47% of the portfolio value in this 13F filing.
- 6 other tracked managers reported the same kind of change for Q3 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 15, 2025InsiderCEO sold ~$249K of CYTK shares in the open market
- Sep 16, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
- Sep 23, 2025InsiderOfficer sold ~$99K of CYTK shares in the open market
- Sep 30, 2025InsiderDirector sold ~$369K of CYTK shares in the open market
- Oct 6, 2025InsiderDirector sold ~$405K of CYTK shares in the open market
- Oct 7, 2025InsiderOfficer sold ~$121K of CYTK shares in the open market
- Oct 9, 2025CongressDisclosed purchase of CYTK — reported range $1,001 - $15,000
- Oct 16, 2025InsiderCEO sold ~$300K of CYTK shares in the open market
- Oct 21, 2025InsiderOfficer sold ~$123K of CYTK shares in the open market
- Oct 27, 2025InsiderDirector sold ~$257K of CYTK shares in the open market
- Oct 30, 2025InsiderCEO sold ~$314K of CYTK shares in the open market
- Nov 4, 2025InsiderOfficer sold ~$137K of CYTK shares in the open market
- Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
- Nov 11, 2025InsiderDirector sold ~$337K of CYTK shares in the open market
- Nov 13, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 13, 2025, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Jeffrey J. Hessekiel, pursuant to which Mr. Hessekiel has agreed to serve as the Company’s Executive Vice President, Chief Legal and Administrative Officer, effective as of November 14, 2025 (the “Start Date”).”
What came next
- Nov 18, 2025InsiderOfficer sold ~$146K of CYTK shares in the open market
- Nov 19, 2025InsiderDirector sold ~$324K of CYTK shares in the open market
- Dec 1, 2025Insider · 2 peopleInsiders: 2 sales (~$2.0M)
- Dec 2, 2025Insider · 2 peopleInsiders: 2 sales (~$700K)
- Dec 5, 2025InsiderOfficer sold ~$3.46M of CYTK shares in the open market
- Dec 8, 2025InsiderOfficer sold ~$69K of CYTK shares in the open market
- Dec 16, 2025InsiderOfficer sold ~$135K of CYTK shares in the open market
- Dec 22, 2025InsiderDirector sold ~$1.32M of CYTK shares in the open market
- Dec 29, 2025InsiderOfficer sold ~$113K of CYTK shares in the open market
- Jan 2, 2026Insider · 1 personInsiders: 2 sales (~$113K)
- Jan 5, 2026InsiderOfficer sold ~$904K of CYTK shares in the open market
- Feb 2, 2026InsiderOfficer sold ~$55K of CYTK shares in the open market
- Feb 5, 2026InsiderOfficer sold ~$929K of CYTK shares in the open market
- Feb 24, 2026Company filing · Form 8-K · ResultsReported its results
- Mar 2, 2026Insider · 2 peopleInsiders: 2 sales (~$361K)
- Mar 5, 2026Insider · 1 personInsiders: 2 sales (~$1.6M)
- Mar 9, 2026Insider · 3 peopleInsiders: 3 sales (~$815K)
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Cytokinetics
For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CYTK page.
How this filing works
Explore the data
Common questions
What does this filing report about Cytokinetics (CYTK) stock?
Frazier Life Sciences Management, L.P. added to its stake in Cytokinetics, per its Q3 2025 13F. Now 890K shares, $48.9M reported value, 1.5% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Sep 30, 2025. Filed: Nov 14, 2025.
What stands out in this filing?
554,731 shares in Q2 2025, 890,445 now (+60.5% in share count). Reported at $48.9M, 1.47% of the portfolio value in this 13F filing. 6 other tracked managers reported the same kind of change for Q3 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Cytokinetics recently?
For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days. They are listed on the CYTK page.
Does this mean CYTK stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Cytokinetics
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
Everything OQRO holds on this company is on its CYTK page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
